Abstract
Pharmaceutical companies face twin pressures of improving the throughput of new products and responding to increased requirements by regulatory bodies for risk evaluation and mitigation both pre- and post-marketing. This paper gives a brief overview of flexible outcome models to improve the accuracy of these studies. The focus is on the discovery of niche populations in secondary analysis and monitoring of adverse events in observational studies of new products. Analytical results illustrate the power of the methods and they can be mapped onto Boolean filters to represent populations with particular benefit/risk ratios
Original language | Unknown |
---|---|
Title of host publication | IEEE International Joint Conference on Neural Networks (IJCNN) |
Pages | 1-8 |
DOIs | |
Publication status | Published - 1 Jan 2010 |
Event | International Joint Conference on Neural Networks (IJCNN) - Duration: 1 Jan 2010 → … |
Conference
Conference | International Joint Conference on Neural Networks (IJCNN) |
---|---|
Period | 1/01/10 → … |